World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
112
Citations
82364
World Ranking
5043
National Ranking
2731

Arthur Kavanaugh publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Arthur Kavanaugh sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 681 publications — 79th percentile

79% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Arthur Kavanaugh D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Arthur Kavanaugh sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 112 D-Index — 75th percentile

75% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Arthur Kavanaugh is affiliated with the University of California, San Diego in the United States. Their primary research spans the fields of Medicine and Immunology and Microbiology, with a significant focus on Rheumatology, Immunology, Hematology, Genetics, and Pathology and Forensic Medicine.

The research topics that Kavanaugh has most frequently addressed include:

  • Spondyloarthritis Studies and Treatments
  • Psoriasis: Treatment and Pathogenesis
  • Autoimmune and Inflammatory Disorders Research
  • Rheumatoid Arthritis Research and Therapies
  • Chronic Lymphocytic Leukemia Research
  • Dermatology and Skin Diseases
  • Fibromyalgia and Chronic Fatigue Syndrome Research

Kavanaugh has published extensively in several venues, with the most frequent publication outlets being:

  • Annals of the Rheumatic Diseases
  • The Journal of Rheumatology
  • ACR Open Rheumatology
  • Arthritis Research & Therapy
  • Arthritis & Rheumatology

Some of Kavanaugh's recent papers include:

  • "2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases" (2020, Arthritis & Rheumatology)
  • "Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021" (2022, Nature Reviews Rheumatology)
  • "Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies" (2020, Journal of the American Academy of Dermatology)
  • "Psoriatic arthritis" (2021, Nature Reviews Disease Primers)
  • "Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial" (2020, The Lancet)

Kavanaugh has collaborated frequently with a set of co-authors, among them:

  • Philip J. Mease, with 41 joint publications
  • Dafna D. Gladman, with 27 joint publications
  • Laura C. Coates, with 23 joint publications
  • Alexis Ogdie, with 21 joint publications
  • Enrique R. Soriano, with 16 joint publications

Best Publications

  • 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.

    Daniel Aletaha;Tuhina Neogi;Alan J. Silman;Julia Funovits

  • 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis

    Jasvinder A. Singh;Kenneth G. Saag;S. Louis Bridges;Elie A. Akl

  • The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment

    Ferdinand C Breedveld;Michael H Weisman;Arthur F Kavanaugh;Stanley B Cohen

  • 2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis

    Jasvinder A. Singh;Daniel E. Furst;Aseem Bharat;Jeffrey R. Curtis

  • Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti–tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: A randomized, placebo‐controlled, 52‐week trial

    Edward C. Keystone;Arthur F. Kavanaugh;John T. Sharp;Hyman Tannenbaum

  • The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial.

    Paul Emery;Roy Fleischmann;Anna Filipowicz-Sosnowska;Joy Schechtman

  • 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis: ACR RA Treatment Recommendations

    Jasvinder A. Singh;Kenneth G. Saag;S. Louis Bridges;Elie A. Akl

  • Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010

    D. E. Furst;E. C. Keystone;J. Braun;F. C. Breedveld

  • Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis

    Laura C. Coates;Arthur Kavanaugh;Philip J. Mease;Enrique R. Soriano

  • Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2) : a randomised, double-blind, placebo-controlled, phase 3 trial

    Iain B McInnes;Philip J Mease;Bruce Kirkham;Arthur Kavanaugh

  • Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial

    C Antoni;G G Krueger;K de Vlam;C Birbara

  • Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial

    Iain B McInnes;Arthur Kavanaugh;Alice B Gottlieb;Lluís Puig

  • Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT).

    Christian E. Antoni;Arthur Kavanaugh;Bruce Kirkham;Zuhre Tutuncu

  • Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial

    Christopher Ritchlin;Proton Rahman;Arthur Kavanaugh;Iain B McInnes

  • Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis.

    Philip J. Mease;Iain B. McInnes;Bruce Kirkham;Arthur Kavanaugh

  • Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial

    Alice Gottlieb;Alan Menter;Alan Mendelsohn;Yaung-Kaung Shen

  • Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial

    Cem Gabay;Paul Emery;Ronald van Vollenhoven;Ara Dikranian

  • Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study.

    Arthur Kavanaugh;Iain McInnes;Philip Mease;Gerald G. Krueger

  • Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies.

    Hal M. Hoffman;Martin L. Throne;N. J. Amar;Mohamed Sebai

  • Treatment recommendations for psoriatic arthritis

    C. T. Ritchlin;A. Kavanaugh;D. D. Gladman;P. J. Mease

Frequent Co-Authors

Philip J. Mease
Philip J. Mease University of Washington
Dafna D. Gladman
Dafna D. Gladman Toronto Western Hospital
Christopher T. Ritchlin
Christopher T. Ritchlin University of Rochester Medical Center
Iain B. McInnes
Iain B. McInnes University of Glasgow
Alice B. Gottlieb
Alice B. Gottlieb Icahn School of Medicine at Mount Sinai
Désirée van der Heijde
Désirée van der Heijde Leiden University Medical Center
Paul Emery
Paul Emery University of Leeds
Philip S. Helliwell
Philip S. Helliwell University of Leeds
Josef S. Smolen
Josef S. Smolen Medical University of Vienna
Edward C. Keystone
Edward C. Keystone University of Toronto

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring alternative online degrees can open doors to rewarding careers in healthcare, even if studying Medicine in the USA isn’t your chosen path. Many students are turning to remote learning for flexibility and accessibility while advancing in clinical or administrative roles.

For those interested in leadership and management, earning a master’s degree from cahme accredited online healthcare administration programs can help you qualify for top positions in hospitals and health systems. If you’re a registered nurse aiming to boost your credentials, an rn to bsn online with no clinicals program offers a convenient pathway to a bachelor’s degree without the need for on-site requirements.

Nurses interested in advanced practice and leadership roles can fast-track their education through the shortest dnp program online. Additionally, several reputable dnp programs online offer flexible coursework to accommodate busy professionals.

As healthcare continues to evolve, these online degree options provide diverse avenues for career advancement, skill-building, and increased impact in the medical field.

Best Scientists Citing Arthur Kavanaugh

Trending Scientists

Recently Published Articles